Stephens Inc. AR Has $1.37 Million Position in Baxter International Inc (BAX)

Stephens Inc. AR boosted its holdings in Baxter International Inc (NYSE:BAX) by 10.9% during the first quarter, HoldingsChannel.com reports. The fund owned 16,903 shares of the medical instruments supplier’s stock after purchasing an additional 1,660 shares during the period. Stephens Inc. AR’s holdings in Baxter International were worth $1,374,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BAX. Vanguard Group Inc grew its stake in Baxter International by 1.3% during the third quarter. Vanguard Group Inc now owns 36,398,931 shares of the medical instruments supplier’s stock worth $2,805,993,000 after buying an additional 470,198 shares during the last quarter. Northern Trust Corp lifted its position in shares of Baxter International by 1.6% during the fourth quarter. Northern Trust Corp now owns 8,615,513 shares of the medical instruments supplier’s stock worth $567,073,000 after purchasing an additional 136,476 shares in the last quarter. Norges Bank acquired a new position in shares of Baxter International during the fourth quarter worth approximately $549,458,000. Veritas Asset Management LLP lifted its position in shares of Baxter International by 1.0% during the first quarter. Veritas Asset Management LLP now owns 7,850,949 shares of the medical instruments supplier’s stock worth $638,361,000 after purchasing an additional 77,608 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Baxter International by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 6,444,204 shares of the medical instruments supplier’s stock worth $423,409,000 after purchasing an additional 297,006 shares in the last quarter. 86.12% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE BAX opened at $75.98 on Friday. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $82.25. The company has a market capitalization of $39.23 billion, a P/E ratio of 24.91, a price-to-earnings-growth ratio of 1.81 and a beta of 0.96. The company has a current ratio of 1.83, a quick ratio of 1.30 and a debt-to-equity ratio of 0.50.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.08. Baxter International had a net margin of 14.27% and a return on equity of 20.04%. The business had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.61 billion. During the same period in the prior year, the business posted $0.70 earnings per share. Baxter International’s revenue was down 1.7% compared to the same quarter last year. Research analysts predict that Baxter International Inc will post 3.32 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Friday, June 7th will be issued a $0.22 dividend. This is a positive change from Baxter International’s previous quarterly dividend of $0.19. This represents a $0.88 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Thursday, June 6th. Baxter International’s dividend payout ratio is currently 24.92%.

A number of equities analysts have recently issued reports on BAX shares. Zacks Investment Research lowered shares of Baxter International from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. Piper Jaffray Companies reiterated an “overweight” rating and set a $80.00 target price on shares of Baxter International in a research report on Friday, February 1st. Barclays upgraded shares of Baxter International from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $67.00 to $72.00 in a research report on Friday, February 1st. Morgan Stanley upped their target price on shares of Baxter International from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 5th. Finally, Wells Fargo & Co upped their target price on shares of Baxter International from $80.00 to $89.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 3rd. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $78.69.

In related news, Director Thomas T. Stallkamp sold 1,000 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $75.16, for a total value of $75,160.00. Following the transaction, the director now directly owns 6,780 shares in the company, valued at $509,584.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John D. Forsyth sold 1,500 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $75.92, for a total transaction of $113,880.00. Following the completion of the transaction, the director now owns 31,703 shares in the company, valued at $2,406,891.76. The disclosure for this sale can be found here. Insiders sold 5,057,187 shares of company stock worth $386,297,619 over the last 90 days. 0.70% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Stephens Inc. AR Has $1.37 Million Position in Baxter International Inc (BAX)” was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/18/stephens-inc-ar-has-1-37-million-position-in-baxter-international-inc-bax.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Recommended Story: How does new data get added to a blockchain?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.